Ionis Pharmaceuticals Inc (NASDAQ:IONS) went lower by -2.05% to close at $ 31.46. The company exchanged total volume of 0 shares throughout course of last trade however it holds an average trading capacity of 2.03 million shares.
The company is trading above its 50-day moving averages of 31.29 and up from 200-day moving averages of 30.17. The firm has price to book ratio of 34.91 and its price to sale ratio was 22.06.
According to ZACKS data, different Brokerage Firms rated the IONS stock about their BUY, SELL or HOLD recommendations. Currently shares have been suggested as BUY from 1 brokerage firms and recommended as Strong Buy by 4 brokerage firms.1 brokerage firms have issued Sell rating for the company and Strong Sell rating was issued by 0 brokerage firms.6 brokerage firms have rated the company as a Hold. The Corporation has average brokerage recommendation (ABR) of 2.33 based on consensus of the brokerage firms issuing ratings.
The average true range of Ionis Pharmaceuticals, Inc.’s (IONS) is recorded at 1.91 and the relative strength index of the stock stands 60.12. The stock price is going above to its 52 week low with 60.57% and lagging behind from its 52 week high with -45.25%. Analyst recommendation for this stock stands at 2.50. A look on the firm performance, its monthly performance is -8.33% and a quarterly performance of -12.51%. The stock price is trading downbeat from its 200 days moving average with -4.28% and up from 50 days moving average with 1.65%.
Charles River Laboratories International, Inc. (NYSE:CRL) surged +2.58% and closed the trade at $ 72.10. The company recorded a trading capacity of 817.52 thousand shares above its three months average daily volume of 400.73 thousand shares. During the last trade, shares reached to high price of $72.55 and touched the low price of $68.71. The stock’s 50-day moving average is noted at $79.59 and its 200-day moving average is stands at $82.53.
Additionally, the company has a PE ratio of 24.37 and has EPS of 2.96. The company has market capitalization of $3.40B.
CRL stock has received ratings from many brokerage firms according to ZACKS. Currently shares have been rated as Buy from 0 brokerage firms and 8 brokerage firms say as Strong Buy. 0 brokerage firms have suggested Sell for the company. 5 brokerage firms have recommended as a Hold. Strong Sell rating was given by 2 brokerage firms. The Company has average brokerage recommendation (ABR) of 2.2 based on consensus of the ZACKS brokerage firms.
Charles River Laboratories International, Inc.’s (CRL) has price-to-cash ratio of 31.28 and price to sale ratio of 2.26. The company net profit margin is 9.10% and gross profit margin is 38.70%. A look on the firm performance, its monthly performance is -13.63% and a quarterly performance of -13.27%. The stock price is moving down from its 20 days moving average with -6.95% and isolated negatively from 50 days moving average with -10.30%.